Organization
Azevan Pharmaceuticals
2 clinical trials
Clinical trial
An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)Status: Completed, Estimated PCD: 2016-05-01
Clinical trial
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)Status: Completed, Estimated PCD: 2018-09-10